Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547728 · ClinicalTrials.gov registry record · Phase 4
Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery
A Phase 4 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 42
- Enrollment target
NCT01547728: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT01547728 is a Phase 4 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01547728, a Phase 4 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 42 participants
- Enrollment target
Study Summary
The objective of this study is to prospectively evaluate the response of recombinant antithrombin (rAT) (ATRYN) in patients who are heparin resistant and are scheduled to undergo cardiac surgery.
Interventions
- DRUG Recombinant antithrombin (rhAT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01547728
The ClinicalTrials.gov registry entry for NCT01547728 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant antithrombin (rhAT) is the first listed.
NCT01547728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01547728 about?
NCT01547728 is a clinical study titled "Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery". The objective of this study is to prospectively evaluate the response of recombinant antithrombin (rAT) (ATRYN) in patients who are heparin resistant and are scheduled to undergo cardiac surgery.
What is the current status of trial NCT01547728?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 42 participants. The study started on 2012-02. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01547728?
The interventions under investigation include: Recombinant antithrombin (rhAT) (DRUG).
Who is sponsoring clinical trial NCT01547728?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.